-
4 new drugs were approved for new indications in China, from Novartis, Merck, Roche, Chia Tai Tianqing
Time of Update: 2022-06-16
Recently, the official website of China's National Medical Products Administration (NMPA) announced that a number of new drugs have been approved for new indications in China, including Novartis' innovative biological agent omalizumab, Merck's (MSD) antifungal drug posaconazole, Roche (Roche) anti-IL-6R antibody tocilizumab, Chia Tai Tianqing multi-target tyrosine kinase inhibitor (TKI) anlotinib, etc.
-
Novartis nuclear drug approved by FDA: Pluvicto
Time of Update: 2022-04-29
On March 23, 2022, Novartis announced that 177Lu-PSMA-617 was approved by the FDA for the treatment of PSMA-positive, treatment-progressed castration-resistant prostate cancer under the trade name Pluvicto .
Novartis also has a number of nuclear drugs under development, most of which use the lutetium-177 isotope .
-
The FDA has accelerated its approval, and Novartis, AstraZeneca, Roche, etc. are optimistic, and "alternative" conjugate drugs are on the rise!
Time of Update: 2021-09-12
On February 26, the biopharmaceutical company Oncopeptides announced that the FDA has accelerated the approval of its PDC drug Pepaxto (melphalan flufenamide, also known as melflufen) to be marketed for use in combination with dexamethasone.
-
Inventory of new drug approvals in the past 5 years: Novartis has the most revenue, Roche, Eli Lilly, and AbbVie have the most revenue
Time of Update: 2021-08-05
Novartis may have the most new drug approvals, but Roche, Lilly and AbbVie's launches win on value: report 2.
Novartis may have the most new drug approvals, but Roche, Lilly and AbbVie's launches win on value: report 2.
-
Novartis has announced that a new drug for allergic conjunctivitis has been officially approved in China
Time of Update: 2021-01-04
Pataday as an upgraded version of olotatad eye drops hydrochloric acid, while continuing to maintain dual-acting anti-sensitivity, will also use the frequency of reduction, is conducive to improving treatment compliance, and further standardize the management of patient self-medication.
-
Novartis has announced that a new drug for allergic conjunctivitis has been officially approved in China
Time of Update: 2021-01-02
It increased the concentration of olotatin hydrochloric acid to 0.2%, not only continue to maintain the dual-effect anti-sensitivity mechanism, but also reduce the frequency of use, once a day, can be 24 hours long-lasting and effective, for China's allergic conjunctivitis patients have brought more convenient treatment options.
-
Novartis' 3 new biologic drugs were approved in China today for clinical targeting PD-1 TGF-β TIM-3
Time of Update: 2020-10-06
according to CDE's official website, the three new drugs were approved clinically in China, and the proposed adaptations are: MBG453, NIS793 single drug or a joint use with PDR001 to treat bone marrow fibrosis.
-
Novartis' 3 new biologic drugs were approved in China today for clinical targeting PD-1 TGF-β TIM-3
Time of Update: 2020-10-03
On September 17, China's State Drug Administration's Drug Review Center (CDE) announced that Novartis' three new Class 1 biologic drugs have been approved for clinical trials, namely TGF-beta inhibitor NIS793, PD-1 inhibitor PDR001, and single-clone antibody MBG453 targeting TIM-3 receptors.
-
varieties approved, anesthesia field a number of declarations, Novartis, Howson, a magenta ...
Time of Update: 2020-08-13
domestic review and approval, new acceptance of this week CDE new report production acceptance number 27, a total of 18 varieties, of which Shumore glucose sodium injection, tirano sodium dispersion tablets received attention, more dynamic see the following table: Shu more glucose sodium patent is about to expire, more than 10 enterprises competing for the first imitation, Zhejiang Xianyuska than Pharmaceutical Co., Ltd. Shu more glucosaride injection application has been accepted.
-
Five new Novartis drugs were approved in Japan yesterday.
Time of Update: 2020-07-31
On June 29th Novartis announced that five of its new drugs had been approved for listing by Japan's Ministry of Health, Labour and Welfare.
-
The biggest winner of the 2020 innovation drug was approved: Novartis.
Time of Update: 2020-07-29
In the first half of 2020, the FDA approved 25 new drugs (including new molecular entities and new biological products), up from 14 in the same period in 2019, and the EUROPEAN Union EMA approved 21
-
Great praise! Five new Novartis drugs were approved in Japan on the same day: Tabrecta, Entresto, Mayzent, Enerzair and Atectura.
Time of Update: 2020-07-19
, 2020 /PRNewswire/ -- Novartis has announced that Japan's Ministry of Health, Labour (MHLW) has approved five drugs simultaneously: - Tabrecta (capinmatib, caprectib, Originally known as INC28
-
New drugs for rare diseases! Novartis anti-inflammatory drug Ilaris approved by FDA: the first drug to treat adult Stila disease (AOSD) !
Time of Update: 2020-06-25
, June 17, 2020 /PRNewswire / -- The U.S Food and Drug Administration ( FDA ) recently approved Novartis anti-inflammatory drug Ilaris (Elili, generic name: canakimumab, kanamono), for the treatm
-
FDA approves first drug for Still disease: Novartis's leukocyte interleukin-1 monoantigen cankinumab
Time of Update: 2020-06-25
Following a priority review, the U.S Food and Drug administration has approved Novartis' Ilaris (canakinumab) as the first treatment for active Still disease, including adult incurable Still disea
-
The biggest winner of innovative drugs approved in 2019: Novartis
Time of Update: 2020-06-19
As of December 28, the U.S FDA approved 48 new drugs (including new molecular entities and new biological products), slightly lower than the 59 in 2018; the EU EMA approved 37 new drugs (including new